PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 368.60
Bid: 368.40
Ask: 368.80
Change: 1.20 (0.33%)
Spread: 0.40 (0.109%)
Open: 360.20
High: 369.20
Low: 360.20
Prev. Close: 367.40
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Third Quarter Trading Update

8 Feb 2018 07:00

RNS Number : 2808E
QinetiQ Group plc
08 February 2018
 

News release

 

QinetiQ Group plc

 Third Quarter Trading Update

8 February 2018

QinetiQ Group plc ('QinetiQ' or 'the Group') today issues a trading update for its third quarter performance.

Maintaining expectations

Underlying trading for the Group was as expected during the third quarter and the Group maintains its expectations for overall performance for FY18.

EMEA Services

In EMEA Services trading for the period was in line with expectations.

The Company is bidding for a number of new opportunities with UK Government that will enable enhanced capability while also driving cost efficiencies. Although the UK environment continues to be challenging as previously announced at our 1H results, this environment creates opportunities for QinetiQ and we remain well placed to support our customers to achieve their objectives.

Internationally, QinetiQ continued to make good progress, particularly in Australia with positive organic growth and in the Middle East where we have seen strong demand for our advisory services.

Global Products

Trading in Global Products for the period was in line with expectations with good order performance in North America.

Strategy update

QinetiQ continues to make good progress implementing its strategy to become a more customer focused and international company, helping customers improve their capabilities while addressing budgetary concerns.

We are making positive steps in modernising UK Defence Test and Evaluation:

·

As result of our strategic investment into UK T&E through the amended Long Term Partnering Agreement ("LTPA") contract, we delivered the first flights of our new aircraft and signed our first multi-year £6m contract from the Royal Netherlands Air Force to train Dutch test pilots and flight test engineers until at least 2022.

 

·

Under the LTPA contract, we received a £9m order to modernise and develop Electro Magnetic Open Sea Ranges which play a vital role in helping to protect and ensure the survivability of all Royal Navy surface vessels and submarines.

 

We continue to build an international company through growth in our US and Australian home countries and wider international markets:

·

In the US we won US$8m of orders for TALON robots from key defence customers.

 

·

Reflecting our deepening relationship with the Australian Department of Defence, an additional AU$16m has been allocated to our Air 7000 strategic support partner contract, which supports the acquisition of airborne maritime surveillance capability.

 

·

We signed our first £3m contract for the supply of aerial targets and services to a customer in the Middle East, further building our presence within the region.

 

 

We continue to advance our innovation strategy across our Company: 

·

Our commercial and business model innovation has supported the signing of our first weapon system contract under our Strategic Enterprise framework which has transformed the provision of aircraft test and evaluation services.

 

·

As an example of our focus on disruptive technology, we are at the leading edge of laser directed energy weapon development, booking further work in the period as well as recently establishing our centre of excellence for the technology.

 

 

Pension surplus

 

Following the latest triennial valuation and discussions with QinetiQ's pension scheme trustees, the Company has a confirmed actuarial pension surplus of £140.5 million as at 30 June 2017. Consequently, the Company will cease making cash deficit recovery payments of approximately £10.5 million per annum from March 2018. 

 

 

 

For further information please contact:

 

David Bishop, Group Director Investor Relations and Communications:

+44 (0) 7920 108675

Ian Brown, Group Head of Investor Relations:

+44 (0) 7908 251123

Jon Hay-Campbell, Group Head of External Communications:

+44 (0) 7500 856953

 

About QinetiQ:

 

QinetiQ is a leading science and engineering company operating primarily in the defence, security and aerospace markets. We work in partnership with our customers to solve real world problems through innovative solutions delivering operational and competitive advantage. Visit our website www.QinetiQ.com. Follow us on LinkedIn and Twitter @QinetiQ. Visit our blog www.QinetiQ-blogs.com.

 

The information communicated in this announcement contains inside information for the purposes of Article. 7 of the Market Abuse Regulation (EU) No. 596/2014

 

 

Disclaimer

This document contains certain forward-looking statements relating to the business, strategy, financial performance and results of the Company and/or the industry in which it operates. Actual results, levels of activity, performance, achievements and events are most likely to vary materially from those implied by the forward-looking statements. The forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words 'believes',' expects', 'predicts', 'intends', 'projects', 'plans', 'estimates', 'aims', 'foresees', 'anticipates', 'targets', 'goals', 'due', 'could', 'may', 'should', 'potential', 'likely' and similar expressions, although these words are not the exclusive means of doing so. These forward-looking statements include, without limitation, statements regarding the Company's future financial position, income growth, impairment charges, business strategy, projected levels of growth in the relevant markets, projected costs, estimates of capital expenditures, and plans and objectives for future operations. Forward-looking statements contained in this announcement regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Nothing in this document should be regarded as a profit forecast.

The forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources, contained in this announcement are solely opinions and forecasts which are uncertain and subject to risks. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to be correct. Actual results may differ materially from those expressed or implied by these forward-looking statements. A number of factors could cause actual events to differ significantly and these are set out in the principal risks and uncertainties section of this document. Most of these factors are difficult to predict accurately and are generally beyond the control of the Company. Any forward-looking statements made by, or on behalf of, the Company speak only as of the date they are made. Save as required by law, the Company will not publicly release the results of any revisions to any forward-looking statements in this document that may occur due to any change in the Directors' expectations or to reflect events or circumstances after the date of this document.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQVLBBVLFXBBD
Date   Source Headline
20th Nov 201710:53 amRNSDirector/PDMR Shareholding
16th Nov 20177:00 amRNSInterim Results
10th Nov 20173:57 pmRNSDirector/PDMR Shareholding
1st Nov 20178:19 amRNSBlock listing Interim Review
18th Oct 20174:46 pmRNSHolding(s) in Company
10th Oct 20174:03 pmRNSHolding(s) in Company
10th Oct 201712:39 pmRNSDirector/PDMR Shareholding
6th Oct 20174:35 pmRNSHolding(s) in Company
29th Sep 20177:00 amRNSPre-Close Trading Statement
22nd Sep 20178:08 amRNSDirector/PDMR Shareholding
12th Sep 20172:08 pmRNSDirector/PDMR Shareholding
8th Sep 201710:43 amRNSDirector/PDMR Shareholding
5th Sep 20171:51 pmRNSHolding(s) in Company
4th Sep 20171:02 pmRNSDirector/PDMR Shareholding
4th Sep 201710:27 amRNSHolding(s) in Company
23rd Aug 201712:02 pmRNSHolding(s) in Company
22nd Aug 20174:19 pmRNSHolding(s) in Company
14th Aug 20173:52 pmRNSDirector/PDMR Shareholding
26th Jul 201712:23 pmRNSDirector/PDMR Shareholding
25th Jul 20173:43 pmRNSDirector/PDMR Shareholding
25th Jul 20179:41 amRNSDirector/PDMR Shareholding
24th Jul 20175:09 pmRNSDirector/PDMR Shareholding
24th Jul 20172:31 pmRNSDirector/PDMR Shareholding
21st Jul 201711:18 amRNSDirector/PDMR Shareholding
19th Jul 20174:05 pmRNSAGM Statement
19th Jul 20177:00 amRNSFirst Quarter Trading Update
13th Jul 20173:30 pmRNSDirector/PDMR Shareholding
11th Jul 20174:15 pmRNSDirector/PDMR Shareholding
7th Jul 20174:13 pmRNSAnnual Financial Report
23rd Jun 20179:40 amRNSDirector/PDMR Shareholding
21st Jun 20175:08 pmRNSDirector/PDMR Shareholding
13th Jun 20173:55 pmRNSAnnual Financial Report
12th Jun 20172:56 pmRNSDirector/PDMR Shareholding
25th May 20177:00 amRNSFull Year Results 2017
10th May 20174:00 pmRNSDirector/PDMR Shareholding
5th May 20174:42 pmRNSBlock listing Interim Review
12th Apr 20174:12 pmRNSDirector/PDMR Shareholding
31st Mar 20173:03 pmRNSTotal Voting Rights
28th Mar 20171:47 pmRNSTransaction in Own Shares 27 Mar 17 - Replacement
27th Mar 20175:48 pmRNSTransaction in Own Shares
24th Mar 20175:13 pmRNSTransaction in Own Shares
23rd Mar 20175:34 pmRNSTransaction in Own Shares
22nd Mar 20175:45 pmRNSTransaction in Own Shares
21st Mar 20175:31 pmRNSTransaction in Own Shares
20th Mar 20175:18 pmRNSTransaction in Own Shares
17th Mar 20175:53 pmRNSTransaction in Own Shares
16th Mar 20175:49 pmRNSTransaction in Own Shares
10th Mar 20173:17 pmRNSDirector/PDMR Shareholding
1st Mar 20177:00 amRNSTotal Voting Rights
27th Feb 20175:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.